Elsevier

Clinical Oncology

Volume 19, Issue 6, August 2007, Pages 385-396
Clinical Oncology

Overview
The Hypoxic Tumour Microenvironment, Patient Selection and Hypoxia-modifying Treatments

https://doi.org/10.1016/j.clon.2007.03.001Get rights and content

Abstract

Tumour hypoxia has been found to be a characteristic feature in many solid tumours. It has been shown to decrease the therapeutic efficacy of radiation treatment, surgery and some forms of chemotherapy. Successful approaches have been developed to counteract this resistance mechanism, although usually at the cost of increased short- and long-term side-effects. New methods for qualitative and quantitative assessment of tumour oxygenation have made it possible to establish the prognostic significance of tumour hypoxia. The ability to determine the degree and extent of hypoxia in solid tumours is not only important prognostically, but also in the selection of patients for hypoxia-modifying treatments. To provide the best attainable quality of life for individual patients it is of increasing importance that tools be developed that allow a better selection of patients for these intensified treatment strategies. Several genes and proteins involved in the response to hypoxia have been identified as potential candidates for future use in predictive assays. Although some markers and combinations have shown potential benefit and are associated with treatment outcome, their clinical usefulness needs to be validated in prospective trials. A review of published studies was carried out, focusing on the assessment of tumour hypoxia, patient selection and the possibilities to overcome hypoxia during treatment.

Introduction

The response to cancer treatment is largely influenced by the tumour microenvironment. One of the most important factors playing a crucial role in this process is the existence of hypoxia in solid tumours. It has been shown to decrease the therapeutic efficacy of radiation treatment, surgery and some forms of chemotherapy. In 1955 it was first recognised that human tumours contain regions of hypoxic cells and that the radiocurability of these tumours was limited by hypoxia [1]. With the introduction in the late 1980s of a computerised polarographic needle electrode system, it became possible to measure tumour oxygenation status [2]. It enabled the rapid identification and characterisation of tumour hypoxia and the assessment of its clinical relevance. Hypoxia was found to be a characteristic feature in about 50% of all locally advanced solid tumours, irrespective of their size and histology [3]. Furthermore, clinical studies in carcinomas of the uterine cervix 4, 5 and head and neck 6, 7 showed a correlation between hypoxia and a poor response to radiotherapy. Hypoxic tumours may also be less responsive to chemotherapeutic agents. This has been shown in vitro and in vivo in a variety of tumours 8, 9, 10. Oxygen deprivation induces changes in a variety of cellular processes, such as apoptosis, proliferation and repair, leading to treatment resistance [11].

The causes of hypoxia are multifactorial and include abnormal and chaotic tumour vasculature, impaired blood perfusion, rate of oxygen consumption and anaemia [3]. Severe tumour hypoxia ultimately leads to tissue necrosis, but non-lethal levels of hypoxia may have a strong effect on tumour cell biology. It elicits multiple cellular response pathways that alter gene expression and lead to proteomic changes. These effects, in turn, are capable of promoting increased metastasis, angiogenesis and the selection of cells with diminished apoptotic potential, leading to a worse outcome. Hypoxia may thus provide an overall positive advantage for malignant growth 12, 13.

Several therapeutic approaches have been developed to overcome hypoxia, some being successful and others not. The main focus has been on either eliminating hypoxia by breathing a high oxygen gas mixture such as carbogen [14] and the use of hyperbaric oxygen [15] or by sensitising hypoxic cells to radiation with hypoxic cell sensitisers [16]. Newer approaches, such as gene therapy or the inhibition of response pathways, are currently under investigation. For these treatments to be successful it is important to develop predictive assays reflecting the biological heterogeneity of individual tumours, thereby providing a tool to optimise and better select patients for those treatment strategies. This review summarises the approaches that have been undertaken to counteract tumour hypoxia and highlights the importance of understanding hypoxic response pathways.

Section snippets

Pathophysiology of Tumour Hypoxia

The presence of hypoxic regions is a characteristic pathophysiological property of many solid tumours and has been found in a wide range of human malignancies. It arises as a result of an imbalance between the supply and consumption of oxygen 17, 18, 19. Several major pathogenetic mechanisms are involved, such as abnormal tumour vasculature, limited tissue perfusion and tumour-associated or therapy-associated anaemia leading to a reduced oxygen transport capacity of the blood 3, 17.

Tumour

Hypoxia Modification in Radiotherapy

With the evidence that tumour hypoxia is a characteristic feature and of prognostic significance in patients with carcinoma of the head and neck and the uterine cervix, several treatment modifications have been tested in the clinic. Although a number of trials did not show any benefit, an overview analysis clearly showed that the modification of tumour hypoxia significantly improved radiotherapy outcome, especially in head and neck carcinomas [39]. However, despite these positive data, hypoxic

Patient Selection

Treatment strategies have been developed to counteract tumour resistance mechanisms, although usually at the cost of increased short- and long-term side-effects. To maximise the probability that patients benefit from treatments especially designed to modify tumour hypoxia and to provide the best attainable quality of life for individual patients, it is of great importance to develop tools allowing better selection of patients before treatment. It is known from experimental and human studies

Measurement of Tumour Hypoxia

The observations that linked the existence of hypoxia with a more malignant tumour behaviour have elicited numerous studies to establish the prognostic significance of hypoxia for treatment outcome. The ultimate aim of these studies was to provide a good basis for treatment selection dependent on tumour oxygenation. Therefore, the ability to determine the degree and extent of hypoxia in solid tumours is not only important prognostically but also in the selection of patients for

Conclusion

Tumour hypoxia has, for many years, been the subject of investigation, as it plays a critical role in treatment resistance. Successful approaches have been developed to counteract tumour hypoxia, although most of these treatments are accompanied by an increase in side-effects. Thus far, not one treatment targeting tumour hypoxia is widely accepted in clinical practice, but several phase III trials are currently investigating new strategies. For these treatments to be successful it is important

Acknowledgement

This study was supported by grant KUN 2003-2899 of the Dutch Cancer Society.

References (130)

  • D.G. Hirst

    What is the importance of anaemia in radiotherapy? The value of animal studies

    Radiother Oncol

    (1991)
  • J. Dunst et al.

    Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis

    Int J Radiat Oncol Biol Phys

    (2003)
  • M.I. Koukourakis et al.

    Hypoxia-mediated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer

    Int J Radiat Oncol Biol Phys

    (2004)
  • J. Overgaard et al.

    Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers

    Semin Radiat Oncol

    (1996)
  • J.H.A.M. Kaanders et al.

    Clinical studies of hypoxia modification in radiotherapy

    Semin Radiat Oncol

    (2004)
  • J.H.A.M. Kaanders et al.

    a novel biology-based approach in radiotherapy

    Lancet Oncol

    (2002)
  • A. Rojas et al.

    Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy

    Int J Radiat Oncol Biol Phys

    (1996)
  • J. Bussink et al.

    Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide

    Radiother Oncol

    (1999)
  • J. Bernier et al.

    ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC

    Radiother Oncol

    (1999)
  • P.J. Hoskin et al.

    The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma

    Radiother Oncol

    (2004)
  • I.J. Hoogsteen et al.

    Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck

    Int J Radiat Oncol Biol Phys

    (2006)
  • J. Overgaard et al.

    Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study

    Int J Radiat Oncol Biol Phys

    (1989)
  • B.G. Wouters et al.

    Hypoxia as a target for combined modality treatments

    Eur J Cancer

    (2002)
  • J. Overgaard et al.

    Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck: results from the DAHANCA 5 randomised double-blind placebo-controlled trial

    Lancet Oncol

    (2005)
  • M. Milosevic et al.

    The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure

    Semin Radiat Oncol

    (2004)
  • H. Lyng et al.

    Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia

    Radiother Oncol

    (1997)
  • Q.T. Le et al.

    Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients

    Int J Radiat Oncol Biol Phys

    (2003)
  • M. Nordsmark et al.

    The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study

    Radiother Oncol

    (2006)
  • S.M. Evans et al.

    Prognostic significance of tumor oxygenation in humans

    Cancer Lett

    (2003)
  • D. Thorwarth et al.

    Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients

    Radiother Oncol

    (2006)
  • J.D. Chapman et al.

    Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays

    Radiother Oncol

    (1998)
  • E.G.C. Troost et al.

    Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors

    Radiother Oncol

    (2006)
  • M. Rijpkema et al.

    Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging

    Int J Radiat Oncol Biol Phys

    (2002)
  • M. Nordsmark et al.

    Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas

    Radiother Oncol

    (2003)
  • D.M. Carnell et al.

    An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance

    Int J Radiat Oncol Biol Phys

    (2006)
  • H.W.M. van Laarhoven et al.

    Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer

    Int J Radiat Oncol Biol Phys

    (2006)
  • S.M. Evans et al.

    EF5 binding and clinical outcome in human soft tissue sarcomas

    Int J Radiat Oncol Biol Phys

    (2006)
  • C.W. Pugh et al.

    The von Hippel–Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis

    Semin Cancer Biol

    (2003)
  • K.L. Talks et al.

    The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages

    Am J Pathol

    (2000)
  • R.H. Thomlinson et al.

    The histological structure of some human lung cancers and the possible implications for radiotherapy

    Br J Cancer

    (1955)
  • M. Höckel et al.

    Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements

    Cancer Res

    (1991)
  • J.H.A.M. Kaanders et al.

    Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer

    Cancer Res

    (2002)
  • B.A. Teicher

    Hypoxia and drug resistance

    Cancer Metastasis Rev

    (1994)
  • J.T. Erler et al.

    Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

    Mol Cell Biol

    (2004)
  • L. Harrison et al.

    Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy

    Oncologist

    (2004)
  • Q.T. Le et al.

    Hypoxic gene expression and metastasis

    Cancer Metastasis Rev

    (2004)
  • M. Saunders et al.

    Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide

    Br J Cancer

    (1996)
  • M. Höckel et al.

    Tumor hypoxia: definitions and current clinical, biological and molecular aspects

    J Natl Cancer Inst

    (2001)
  • P. Vaupel et al.

    Treatment resistance of solid tumors. Role of hypoxia and anemia

    Med Oncol

    (2001)
  • A.L. Harris

    Hypoxia—a key regulatory factor of in tumour growth

    Nat Rev Cancer

    (2002)
  • Cited by (0)

    View full text